Starpharma today announced the results of an animal study which shows that a dendrimer-based formulation of doxorubicin was substantially more efficacious in treating secondary tumours of breast cancer (metastases) in lungs than the drug alone.

Starpharma today released its interim report and financial results for the half-year ended 31 December 2012.

Financial Highlights

• Reported loss $1.8M (Dec 2011: $4.7 million)
• R&D tax incentives of $6.8M reported in the half-year
• Cash position at 31 December 2012 $33.2M
• R&D tax incentive receivables at 31 December 2012 $8.1M

Starpharma today released its Appendix 4C - Quarterly Cashflow Report for the period ended 31 December 2012.

The Herald Sun’s Chief Business Writer John Beveridge investigates some of the best strategies to make money on the stock market and profiles Starpharma as having potential, following the results of its Phase III trial for VivaGel as a treatment for BV:

All is not lost, though, because VivaGel still has potential to become the most effective treatment for the complaint and the company's dendrimer technology has numerous other lucrative applications.

In this issue:

›  Phase 3 clinical trial results for treatment of bacterial vaginosis

› Rapid resolution of symptoms; strong patient acceptability for VivaGel^®

› Taxotere’s anti-cancer effect boosted with Starpharma’s dendrimer technology

› Turning over a new leaf in the world of agrochemicals

› Starpharma wins Janssen Company of the Year Award

Download: Shareholder Update: December 2012 ( pdf file, 1MB)

Starpharma today announced the appointment of an additional Vice President of Business Development with extensive pharmaceutical licensing experience.  Ms Eve Williamson, who will commence in the role with Starpharma in the New Year, has worked in the pharmaceutical industry for more than 20 years including senior roles in business development, marketing and sales, pricing and reimbursement, and clinical research.

Starpharma today announced the results of animal trials which show its dendrimer-enhanced version of docetaxel had significantly superior anti-cancer effects across a range of important cancer types when compared to Taxotere (docetaxel).

Starpharma released its AGM Chairman's address and CEO presentation for the meeting held 30th November 2012. Results of voting were released following the meeting.

Starpharma will be hosting investor conference calls to discuss results of the Company’s phase 3 clinical trial for the treatment of bacterial vaginosis.  The calls will be hosted by Starpharma Chief Executive Officer Dr Jackie Fairley.

Starpharma today announced the results of its two phase 3 studies of VivaGel^® for the treatment of bacterial vaginosis (BV).  Both studies showed that VivaGel^® achieved statistically significant Clinical Cure and resolution of patient-reported symptoms of BV at the End of Treatment visit (EOT, 2-5 days post treatment).  However, the primary endpoint of Clinical Cure 2-3 weeks after the cessation of treatment (Test of Cure, TOC visit) was not met.